{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:40:40Z","timestamp":1790286040723,"version":"4.1.0"},"reference-count":180,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1382 , project-ID 403224013"],"award-info":[{"award-number":["SFB1382 , project-ID 403224013"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["533770413"],"award-info":[{"award-number":["533770413"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["403224013"],"award-info":[{"award-number":["403224013"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["535081457"],"award-info":[{"award-number":["535081457"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1382"],"award-info":[{"award-number":["SFB1382"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC\/TR 412"],"award-info":[{"award-number":["CRC\/TR 412"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.medj.2026.101173","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:03:28Z","timestamp":1780499008000},"page":"101173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The thyroid-liver axis in MASLD: From metabolic control to clinical translation"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-3703","authenticated-orcid":false,"given":"Yasmina","family":"Chouik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Caussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101173_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/HEP.0000000000000913","article-title":"Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Qi","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.medj.2026.101173_bib4","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cgh.2025.09.002","article-title":"Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries","volume":"24","author":"Younossi","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101173_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib8","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1210\/en.2003-1312","article-title":"Leptin signaling targets the thyrotropin-releasing hormone gene promoter in vivo","volume":"145","author":"Guo","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2026.101173_bib9","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1530\/JOE-14-0593","article-title":"Regulation of TRH neurons and energy homeostasis-related signals under stress","volume":"224","author":"Joseph-Bravo","year":"2015","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/17446651.2022.2110864","article-title":"Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis","volume":"17","author":"Wirth","year":"2022","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib11","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1210\/en.2014-1302","article-title":"Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism","volume":"155","author":"Bohinc","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2026.101173_bib12","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab091","article-title":"Thyroid Hormone Deiodinases: Dynamic Switches in Developmental Transitions","volume":"162","author":"Hernandez","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2026.101173_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1210\/en.2008-0344","article-title":"Large induction of type III deiodinase expression after partial hepatectomy in the regenerating mouse and rat liver","volume":"150","author":"Kester","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2026.101173_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1677\/joe.1.06354","article-title":"Differential involvement of nuclear factor-kappaB and activator protein-1 pathways in the interleukin-1beta-mediated decrease of deiodinase type 1 and thyroid hormone receptor beta1 mRNA","volume":"189","author":"Kwakkel","year":"2006","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib15","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-13-0573","article-title":"Thyroid: biological actions of \u201cnonclassical\u201d thyroid hormones","volume":"221","author":"Senese","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrendo.2015.205","article-title":"Nongenomic actions of thyroid hormone","volume":"12","author":"Davis","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2011.05.009","article-title":"Coordination of mitochondrial biogenesis by thyroid hormone","volume":"342","author":"Weitzel","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/HEP.0000000000000551","article-title":"Thyroid hormone action and liver disease, a complex interplay","volume":"81","author":"Marino","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/me.2004-0093","article-title":"Thyroid hormone induces rapid activation of Akt\/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts","volume":"19","author":"Cao","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/thy.2007.0247","article-title":"The Nuclear Receptor Signaling Atlas: catalyzing understanding of thyroid hormone signaling and metabolic control","volume":"18","author":"Margolis","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.medj.2026.101173_bib21","first-page":"184","article-title":"Thyroid hormone receptors: multiple forms, multiple possibilities","volume":"14","author":"Lazar","year":"1993","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.medj.2026.101173_bib22","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2337\/db22-0656","article-title":"Adipocyte Thyroid Hormone \u03b2 Receptor-Mediated Hormone Action Fine-tunes Intracellular Glucose and Lipid Metabolism and Systemic Homeostasis","volume":"72","author":"Ma","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.medj.2026.101173_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03491-6","article-title":"Thyroid hormone receptor alpha sumoylation modulates white adipose tissue stores","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101173_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/liv.15759","article-title":"Thyroid hormone receptor alpha modulates fibrogenesis in hepatic stellate cells","volume":"44","author":"Manka","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.medj.2026.101173_bib25","doi-asserted-by":"crossref","first-page":"C1467","DOI":"10.1152\/ajpcell.00575.2006","article-title":"Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC\/IP(3)\/Ca(2+)-dependent downregulation of SRC\/ERK1\/2","volume":"292","author":"Fava","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.medj.2026.101173_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s44324-024-00023-4","article-title":"Thyroid hormone receptor beta (THRB) dependent regulation of diurnal hepatic lipid metabolism in adult male mice","volume":"2","author":"de Assis","year":"2024","journal-title":"NPJ Metab. Health Dis."},{"key":"10.1016\/j.medj.2026.101173_bib27","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/EJE-21-1171","article-title":"The interplay of thyroid hormones and the immune system \u2013 where we stand and why we need to know about it","volume":"186","author":"Wenzek","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib28","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.medj.2026.101173_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41575-024-00991-4","article-title":"Actions of thyroid hormones and thyromimetics on the liver","volume":"22","author":"Sinha","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib30","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1172\/JCI60580","article-title":"Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy","volume":"122","author":"Sinha","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101173_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0014-5793(78)80095-7","article-title":"Effect of thyroxine on acid lipase activity of adult rat liver","volume":"86","author":"Coates","year":"1978","journal-title":"FEBS Lett."},{"key":"10.1016\/j.medj.2026.101173_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1074\/jbc.M115.668673","article-title":"Hepatic FOXO1 Target Genes Are Co-regulated by Thyroid Hormone via RICTOR Protein Deacetylation and MTORC2-AKT Protein Inhibition","volume":"291","author":"Singh","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib33","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.3390\/ijms24054861","article-title":"Hepatic Energy Metabolism under the Local Control of the Thyroid Hormone System","volume":"24","author":"Seifert","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2026.101173_bib34","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1074\/jbc.M211062200","article-title":"A thyroid hormone response unit formed between the promoter and first intron of the carnitine palmitoyltransferase-Ialpha gene mediates the liver-specific induction by thyroid hormone","volume":"278","author":"Jackson-Hayes","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib35","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1074\/jbc.M109.039081","article-title":"Regulation of Pyruvate Dehydrogenase Kinase 4 (PDK4) by Thyroid Hormone","volume":"285","author":"Attia","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib36","doi-asserted-by":"crossref","first-page":"53963","DOI":"10.1074\/jbc.M406028200","article-title":"Peroxisomal proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) enhances the thyroid hormone induction of carnitine palmitoyltransferase I (CPT-I alpha)","volume":"279","author":"Zhang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mce.2008.01.017","article-title":"T3-mediated expression of PGC-1alpha via a far upstream located thyroid hormone response element","volume":"287","author":"Wulf","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1042\/bj3240289","article-title":"Tissue-specific regulation of medium-chain acyl-CoA dehydrogenase gene by thyroid hormones in the developing rat","volume":"324","author":"Djouadi","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.medj.2026.101173_bib39","first-page":"E380","article-title":"T(3) stimulates resting metabolism and UCP-2 and UCP-3 mRNA but not nonphosphorylating mitochondrial respiration in mice","volume":"277","author":"Jekabsons","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.medj.2026.101173_bib40","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1074\/jbc.M112.437970","article-title":"Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone","volume":"288","author":"Thakran","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1677\/JME-09-0107","article-title":"Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors","volume":"44","author":"Lu","year":"2010","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib42","doi-asserted-by":"crossref","first-page":"14078","DOI":"10.1074\/jbc.C110.107375","article-title":"Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner","volume":"285","author":"Adams","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic Messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib44","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tem.2014.07.001","article-title":"Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism","volume":"25","author":"Sinha","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12929-019-0517-x","article-title":"Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases","volume":"26","author":"Chi","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.medj.2026.101173_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam5855","article-title":"Thyroid hormone receptor and ERR\u03b1 coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function","volume":"11","author":"Singh","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.medj.2026.101173_bib47","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101173_bib48","first-page":"383","article-title":"Thyroid hormone. Basis for its hypocholesterolemic effect","volume":"78","author":"Ness","year":"1991","journal-title":"J. Fla. Med. Assoc."},{"key":"10.1016\/j.medj.2026.101173_bib49","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbalip.2007.05.001","article-title":"Activation of the hepatic LDL receptor promoter by thyroid hormone","volume":"1771","author":"Lopez","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.medj.2026.101173_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0005-2760(94)90047-7","article-title":"Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies","volume":"1215","author":"Lagrost","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.medj.2026.101173_bib51","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI114489","article-title":"Role of thyroid hormones in apolipoprotein A-I gene expression in rat liver","volume":"85","author":"Strobl","year":"1990","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101173_bib52","first-page":"R1602","article-title":"Age-related changes in the responsiveness of apolipoprotein A1 to thyroid hormone","volume":"271","author":"Mooradian","year":"1996","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.medj.2026.101173_bib53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1006\/abbi.1995.0061","article-title":"Transcriptional regulation of rat hepatic low-density lipoprotein receptor and cholesterol 7 alpha hydroxylase by thyroid hormone","volume":"323","author":"Ness","year":"1995","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.medj.2026.101173_bib54","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/hep.25861","article-title":"Stimulation of murine biliary cholesterol secretion by thyroid hormone is dependent on a functional ABCG5\/G8 complex","volume":"56","author":"Bonde","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib55","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jhep.2014.06.037","article-title":"Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity","volume":"61","author":"Yan","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib56","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1194\/jlr.M047654","article-title":"Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver","volume":"56","author":"Zhang","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.medj.2026.101173_bib57","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1210\/endo.135.2.8033812","article-title":"Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system","volume":"135","author":"Weinstein","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2026.101173_bib58","doi-asserted-by":"crossref","first-page":"30365","DOI":"10.1074\/jbc.M113.504845","article-title":"FoxO1 deacetylation regulates thyroid hormone-induced transcription of key hepatic gluconeogenic genes","volume":"288","author":"Singh","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abh3839","article-title":"Thyroid hormone signaling promotes hepatic lipogenesis through the transcription factor ChREBP","volume":"14","author":"Mendoza","year":"2021","journal-title":"Sci. Signal."},{"key":"10.1016\/j.medj.2026.101173_bib60","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1074\/jbc.M005894200","article-title":"Thyroid hormone stimulates acetyl-coA carboxylase-alpha transcription in hepatocytes by modulating the composition of nuclear receptor complexes bound to a thyroid hormone response element","volume":"276","author":"Zhang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib61","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1210\/en.2009-0059","article-title":"Carbohydrate response element binding protein gene expression is positively regulated by thyroid hormone","volume":"150","author":"Hashimoto","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2026.101173_bib62","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1210\/en.2006-0116","article-title":"Mouse sterol response element binding protein-1c gene expression is negatively regulated by thyroid hormone","volume":"147","author":"Hashimoto","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2026.101173_bib63","doi-asserted-by":"crossref","first-page":"E513","DOI":"10.1152\/ajpendo.00659.2007","article-title":"Effects of thyrotoxicosis and selective hepatic autonomic denervation on hepatic glucose metabolism in rats","volume":"294","author":"Klieverik","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib64","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.molmed.2013.04.004","article-title":"Energy balance regulation by thyroid hormones at central level","volume":"19","author":"L\u00f3pez","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.medj.2026.101173_bib65","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cmet.2017.06.014","article-title":"Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance","volume":"26","author":"Mart\u00ednez-S\u00e1nchez","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.medj.2026.101173_bib66","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1210\/endo.138.3.4981","article-title":"Effects of thyroid hormone on GLUT4 glucose transporter gene expression and NIDDM in rats","volume":"138","author":"Torrance","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2026.101173_bib67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/endo-129-1-455","article-title":"Thyroid hormone increases muscle\/fat glucose transporter gene expression in rat skeletal muscle","volume":"129","author":"Weinstein","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2026.101173_bib68","first-page":"E109","article-title":"Mechanisms underlying enhanced glycogenolysis in livers of 3,5,3\u2019-triiodothyronine-treated rats","volume":"258","author":"Nebioglu","year":"1990","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.medj.2026.101173_bib69","doi-asserted-by":"crossref","first-page":"E11323","DOI":"10.1073\/pnas.1706801115","article-title":"Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo","volume":"114","author":"H\u00f6nes","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2026.101173_bib70","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1476-5381.2010.01056.x","article-title":"Thyroid hormone potentiates insulin signaling and attenuates hyperglycemia and insulin resistance in a mouse model of type 2 diabetes","volume":"162","author":"Lin","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.medj.2026.101173_bib71","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/152850","article-title":"Why Can Insulin Resistance Be a Natural Consequence of Thyroid Dysfunction?","volume":"2011","author":"Brenta","year":"2011","journal-title":"J. Thyroid Res."},{"key":"10.1016\/j.medj.2026.101173_bib72","article-title":"Association between thyroid hormones and insulin resistance indices based on the Korean National Health and Nutrition Examination Survey","volume":"11","author":"Choi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101173_bib73","doi-asserted-by":"crossref","first-page":"E3451","DOI":"10.1073\/pnas.1506113113","article-title":"Thyroid hormones inhibit TGF-\u03b2 signaling and attenuate fibrotic responses","volume":"113","author":"Alonso-Merino","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2026.101173_bib74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nm.4447","article-title":"Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function","volume":"24","author":"Yu","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101173_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108811","article-title":"Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?","volume":"268","author":"Arvanitakis","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.medj.2026.101173_bib76","article-title":"Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Schwabe","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.medj.2026.101173_bib77","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1089\/thy.2021.0621","article-title":"Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis","volume":"32","author":"Zhou","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.medj.2026.101173_bib78","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.3390\/ijms24065843","article-title":"Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-\u03baB Signaling Pathways in an RGS5-Dependent Manner","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2026.101173_bib79","article-title":"Dissecting Acute Drug-Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver-On-A-Chip Model","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.medj.2026.101173_bib80","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/10715760400029637","article-title":"Redox regulation of thyroid hormone-induced Kupffer cell-dependent IkappaB-alpha phosphorylation in relation to inducible nitric oxide synthase expression","volume":"39","author":"Fern\u00e1ndez","year":"2005","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.medj.2026.101173_bib81","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1515\/BC.2007.101","article-title":"Involvement of Kupffer cell-dependent signaling in T3-induced hepatocyte proliferation in vivo","volume":"388","author":"Fern\u00e1ndez","year":"2007","journal-title":"Biol. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib82","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mam.2004.02.018","article-title":"Tri-iodothyronine differentially induces Kupffer cell ED1\/ED2 subpopulations","volume":"25","author":"Gomes","year":"2004","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.medj.2026.101173_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/srep30990","article-title":"The Thyroid Hormone Receptors Inhibit Hepatic Interleukin-6 Signaling During Endotoxemia","volume":"6","author":"Contreras-Jurado","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101173_bib84","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ajpath.2013.10.006","article-title":"The thyroid hormone triiodothyronine controls macrophage maturation and functions: protective role during inflammation","volume":"184","author":"Perrotta","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.medj.2026.101173_bib85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrcardio.2016.174","article-title":"Thyroid hormones and cardiovascular disease","volume":"14","author":"Jabbar","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.medj.2026.101173_bib86","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/thy.2006.0235","article-title":"Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002)","volume":"17","author":"Aoki","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.medj.2026.101173_bib87","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000499751","article-title":"Prevalence of Undiagnosed Hypothyroidism in Europe: A Systematic Review and Meta-Analysis","volume":"8","author":"Mendes","year":"2019","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.medj.2026.101173_bib88","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib89","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2265.2009.03698.x","article-title":"A high normal TSH is associated with the metabolic syndrome","volume":"72","author":"Ruhla","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib90","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1210\/jc.2006-1718","article-title":"Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects","volume":"92","author":"Roos","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib91","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1210\/jc.2013-1315","article-title":"Clinical review: A review of the clinical consequences of variation in thyroid function within the reference range","volume":"98","author":"Taylor","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib92","doi-asserted-by":"crossref","first-page":"832","DOI":"10.7326\/0003-4819-148-11-200806030-00225","article-title":"Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality","volume":"148","author":"Ochs","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.medj.2026.101173_bib93","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1210\/jc.2004-2225","article-title":"Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population","volume":"90","author":"Knudsen","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib94","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/archinte.168.6.587","article-title":"Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample","volume":"168","author":"Fox","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.medj.2026.101173_bib95","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.14309\/ajg.0000000000000654","article-title":"Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality","volume":"115","author":"Kim","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.medj.2026.101173_bib96","doi-asserted-by":"crossref","first-page":"e3303","DOI":"10.1210\/clinem\/dgaf059","article-title":"Sex Differences in the Association Between Thyroid Hormone Sensitivity and Cardiovascular-Kidney-Metabolic Syndrome","volume":"110","author":"Jiang","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib97","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1210\/clinem\/dgad186","article-title":"Central Sensitivity to Free Triiodothyronine With MAFLD and Its Progression to Liver Fibrosis in Euthyroid Adults","volume":"108","author":"Wan","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib98","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2147\/DMSO.S499517","article-title":"Association of Sensitivity to Thyroid Hormones and Non-Alcoholic Fatty Liver Disease and the Severity of Liver Fibrosis in Euthyroid Adults: A Retrospective Study","volume":"18","author":"Zhou","year":"2025","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.medj.2026.101173_bib99","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhep.2012.02.027","article-title":"Non-alcoholic fatty liver disease across the spectrum of hypothyroidism","volume":"57","author":"Chung","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib100","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10620-011-2006-2","article-title":"Prevalence of hypothyroidism in nonalcoholic fatty liver disease","volume":"57","author":"Pagadala","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.medj.2026.101173_bib101","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/s41598-025-91221-7","article-title":"Exploring the nexus between hypothyroidism and metabolic dysfunction-associated steatotic liver disease: a UK biobank cohort study","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101173_bib102","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1136\/gutjnl-2024-332491","article-title":"Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis","volume":"73","author":"Mantovani","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.medj.2026.101173_bib103","article-title":"Thyroid dysfunction in MASLD: Results of a nationwide study","volume":"7","author":"Yuan","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.medj.2026.101173_bib104","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","article-title":"Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib105","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.dld.2022.06.021","article-title":"Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: A cross-sectional study","volume":"55","author":"Li","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.medj.2026.101173_bib106","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jhep.2012.05.025","article-title":"Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: a prospective case-control study","volume":"57","author":"Xu","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib107","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1210\/jc.2016-1300","article-title":"Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study","volume":"101","author":"Bano","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib108","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1210\/clinem\/dgac393","article-title":"Thyroid Stimulating Hormone Levels Are Associated With Genetically Predicted Nonalcoholic Fatty Liver Disease","volume":"107","author":"Fan","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib109","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1038\/s41598-017-07004-2","article-title":"Metabolic syndrome is associated with an increased incidence of subclinical hypothyroidism - A Cohort Study","volume":"7","author":"Chang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101173_bib110","doi-asserted-by":"crossref","first-page":"E9172","DOI":"10.1073\/pnas.1707797114","article-title":"Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms","volume":"114","author":"Ferrandino","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2026.101173_bib111","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/jcm10132907","article-title":"TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population","volume":"10","author":"Mart\u00ednez-Escud\u00e9","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.medj.2026.101173_bib112","article-title":"Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality","volume":"6","author":"Hartl","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.medj.2026.101173_bib113","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1210\/jc.2009-0212","article-title":"Thyroid hormone-related regulation of gene expression in human fatty liver","volume":"94","author":"Pihlajam\u00e4ki","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib114","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1530\/EC-18-0499","article-title":"Reduced expression of thyroid hormone receptor \u03b2 in human nonalcoholic steatohepatitis","volume":"7","author":"Krause","year":"2018","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.medj.2026.101173_bib115","first-page":"360","article-title":"Expression and function of thyroid hormone receptor variants in normal and chronically diseased human liver","volume":"81","author":"Chamba","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib116","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0140-6736(89)92930-9","article-title":"Thyroid hormone receptor expression in the \u201csick euthyroid\u201d syndrome","volume":"2","author":"Williams","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101173_bib117","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/me.2008-0311","article-title":"Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms","volume":"23","author":"Araki","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib118","doi-asserted-by":"crossref","DOI":"10.1038\/srep43960","article-title":"The ligand-bound thyroid hormone receptor in macrophages ameliorates kidney injury via inhibition of nuclear factor-\u03baB activities","volume":"7","author":"Furuya","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2026.101173_bib119","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41591-023-02602-2","article-title":"An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease","volume":"29","author":"Kendall","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101173_bib120","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jama.1972.03200070084015","article-title":"Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group","volume":"220","year":"1972","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2026.101173_bib121","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1038\/sj.ijo.0801294","article-title":"Thyroid hormones and treatment of obesity","volume":"24","author":"Krotkiewski","year":"2000","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.medj.2026.101173_bib122","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.22572","article-title":"Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist","volume":"49","author":"Cable","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib123","doi-asserted-by":"crossref","first-page":"15490","DOI":"10.1073\/pnas.0702759104","article-title":"Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index","volume":"104","author":"Erion","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2026.101173_bib124","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/01.CIR.88.3.1289","article-title":"Combination treatment with captopril and the thyroid hormone analogue 3,5-diiodothyropropionic acid. A new approach to improving left ventricular performance in heart failure","volume":"88","author":"Pennock","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.medj.2026.101173_bib125","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1161\/CIRCULATIONAHA.108.834424","article-title":"DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study","volume":"119","author":"Goldman","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.medj.2026.101173_bib126","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/324425a0","article-title":"A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity","volume":"324","author":"Underwood","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.medj.2026.101173_bib127","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1074-5521(98)90168-5","article-title":"A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor","volume":"5","author":"Chiellini","year":"1998","journal-title":"Chem. Biol."},{"key":"10.1016\/j.medj.2026.101173_bib128","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1152\/ajpendo.00573.2012","article-title":"Thyroid hormone receptor-\u03b2 agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways","volume":"305","author":"Vatner","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.medj.2026.101173_bib129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10741-008-9122-x","article-title":"Sobetirome: a case history of bench-to-clinic drug discovery and development","volume":"15","author":"Scanlan","year":"2010","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.medj.2026.101173_bib130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/157489011794578473","article-title":"Sobetirome: a selective thyromimetic for the treatment of dyslipidemia","volume":"6","author":"Tancevski","year":"2011","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"key":"10.1016\/j.medj.2026.101173_bib131","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2026.101173_bib132","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101173_bib133","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","article-title":"Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study","volume":"2","author":"Sjouke","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib134","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1096\/fj.08-108464","article-title":"Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit\/reverse nonalcoholic fatty liver in rats","volume":"22","author":"Perra","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.medj.2026.101173_bib135","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jsbmb.2008.06.010","article-title":"Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141","volume":"111","author":"Bryzgalova","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.medj.2026.101173_bib136","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1021\/ja031818y","article-title":"Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver","volume":"126","author":"Erion","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.medj.2026.101173_bib137","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1124\/dmd.108.021642","article-title":"Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist","volume":"36","author":"Fujitaki","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.medj.2026.101173_bib138","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4158\/EP12086.RA","article-title":"Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?","volume":"18","author":"Shoemaker","year":"2012","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.medj.2026.101173_bib139","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1089\/thy.2019.0007","article-title":"A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia","volume":"29","author":"Zhou","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.medj.2026.101173_bib140","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"Kelly","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib141","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib142","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.medj.2026.101173_bib143","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/s41401-024-01303-x","article-title":"A new mechanism of thyroid hormone receptor \u03b2 agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles","volume":"45","author":"Sun","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.medj.2026.101173_bib144","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, \u03b2-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112006","article-title":"Design, synthesis and biological evaluation of novel TR\u03b2 selective agonists sustained by ADME-toxicity analysis","volume":"188","author":"Runfola","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib146","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12808","article-title":"Potential role of two novel agonists of thyroid hormone receptor-\u03b2 on liver regeneration","volume":"53","author":"Perra","year":"2020","journal-title":"Cell Prolif."},{"key":"10.1016\/j.medj.2026.101173_bib147","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313105","article-title":"TG68, a Novel Thyroid Hormone Receptor-\u03b2 Agonist for the Treatment of NAFLD","volume":"22","author":"Caddeo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2026.101173_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1127517","article-title":"Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis","volume":"13","author":"Caddeo","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.medj.2026.101173_bib149","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/4950597","article-title":"CS27109, A Selective Thyroid Hormone Receptor-\u03b2 Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models","volume":"2023","author":"Huang","year":"2023","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib150","article-title":"Discovery of a novel, liver-targeted thyroid hormone receptor-\u03b2 agonist, CS271011, in the treatment of lipid metabolism disorders","volume":"14","author":"Lin","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.medj.2026.101173_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108880","article-title":"Design, synthesis, and biological evaluation of liver-targeting phosphoric acid thyroid hormone receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"164","author":"Lin","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.medj.2026.101173_bib152","article-title":"KYLO-0603, a novel liver-targeting, thyroid hormone receptor-\u03b2 agonist for the inhibition of MASH progression","volume":"20","author":"Lu","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2026.101173_bib153","article-title":"ALG-055009, a potent and selective THR beta agonist for the treatment of NASH, demonstrates significant cholesterol reduction in a diet-induced obese (DIO) mouse efficacy model","volume":"72","author":"Gupta","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/cpdd.1606","article-title":"A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-\u03b2) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants","volume":"15","author":"Charfi","year":"2026","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.medj.2026.101173_bib155","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jhep.2024.08.008","article-title":"Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids","volume":"82","author":"Zhang","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib156","series-title":"ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-\u03b2) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Randomized, Double-Blind, Placebo-controlled Phase 2a HERALD Study","author":"Loomba","year":"2025"},{"key":"10.1016\/j.medj.2026.101173_bib157","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101173_bib158","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cgh.2025.08.009","article-title":"Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial","volume":"24","author":"Xue","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib159","first-page":"13","article-title":"Results From the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients With Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial","volume":"20","author":"Alkhouri","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.medj.2026.101173_bib161","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/apt.70382","article-title":"Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and\/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial","volume":"62","author":"Noureddin","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2026.101173_bib162","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101173_bib163","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2026.101173_bib164","first-page":"S1","article-title":"Two-year time course of biomarker and imaging responses in well-compensated MASH cirrhosis patients treated with Resmetirom. The Liver Meeting: 2025 Abstracts","volume":"82","author":"Alkhouri","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib165","first-page":"S1","article-title":"Sanyal, Arun Resmetirom improves mortality, liver and cardio-renal-metabolic (CRM) outcomes in individuals with metabolic dysfunction-associated steatotic liver disease in routine clinical practice. The Liver Meeting: 2025 Abstracts","volume":"82","author":"Jahagirdar","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib166","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH\/NASH and Moderate to Noncirrhotic Advanced Fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib167","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib168","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","article-title":"Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD","volume":"81","author":"Gawrieh","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib169","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2026.101173_bib170","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJMe2314365","article-title":"Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH","volume":"390","author":"Cusi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101173_bib171","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101173_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100965","article-title":"Non-invasive tests for fibrotic MASH: Decision aids in MASH therapeutics and predictors of liver-related events","volume":"7","author":"Theocharidou","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.medj.2026.101173_bib173","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib174","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/oby.24027","article-title":"Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery","volume":"32","author":"Hall","year":"2024","journal-title":"Obesity"},{"key":"10.1016\/j.medj.2026.101173_bib175","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib176","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174233","article-title":"Weight loss in MASLD restores the balance of liver fatty acid sources","volume":"135","author":"Lambert","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101173_bib177","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2468-1253(25)00128-1","article-title":"Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study","volume":"10","author":"Wong","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.medj.2026.101173_bib178","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1097\/HEP.0000000000001266","article-title":"Letter to the Editor: Alcohol a confounding factor in the assessment of resmetirom therapy","volume":"81","author":"Krag","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.medj.2026.101173_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150742","article-title":"Liver-specific thyroid hormone receptor-\u03b2 agonism alleviates alcoholic steatohepatitis (ASH) in mice","volume":"734","author":"Shahi","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.medj.2026.101173_bib180","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/hbsn-24-568","article-title":"Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease","volume":"13","author":"Lurje","year":"2024","journal-title":"Hepatobiliary Surg. Nutr."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:22:28Z","timestamp":1785900148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026001765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":180,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666634026001765"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101173","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The thyroid-liver axis in MASLD: From metabolic control to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101173"}}